vs
Side-by-side financial comparison of Citius Pharmaceuticals, Inc. (CTXR) and Versus Systems Inc. (VS). Click either name above to swap in a different company.
Citius Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($3.9M vs $2.2M, roughly 1.8× Versus Systems Inc.). Versus Systems Inc. runs the higher net margin — -44.7% vs -238.2%, a 193.5% gap on every dollar of revenue.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.
Versus Systems Inc. operates a proprietary interactive reward platform that integrates with video games, streaming content, live sports broadcasts and mobile apps. It enables content creators and brands to offer personalized real-time prizes to audiences across North America and global digital entertainment markets.
CTXR vs VS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $2.2M |
| Net Profit | $-9.4M | $-964.9K |
| Gross Margin | 80.0% | 0.2% |
| Operating Margin | -228.7% | -54.2% |
| Net Margin | -238.2% | -44.7% |
| Revenue YoY | — | — |
| Net Profit YoY | 8.6% | -19.2% |
| EPS (diluted) | $-0.38 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $2.2M | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $-176.0K | ||
| Q4 24 | — | $0 | ||
| Q2 23 | — | $157.9K | ||
| Q3 22 | — | $316.8K | ||
| Q2 22 | — | $250.7K |
| Q4 25 | $-9.4M | $-964.9K | ||
| Q3 25 | — | $-537.8K | ||
| Q2 25 | — | $672.3K | ||
| Q4 24 | — | $-809.5K | ||
| Q2 23 | — | $-2.3M | ||
| Q3 22 | — | $-3.5M | ||
| Q2 22 | — | $-3.2M |
| Q4 25 | 80.0% | 0.2% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 23 | — | 79.5% | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
| Q4 25 | -228.7% | -54.2% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 23 | — | -840.1% | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
| Q4 25 | -238.2% | -44.7% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -382.0% | ||
| Q4 24 | — | — | ||
| Q2 23 | — | -1462.9% | ||
| Q3 22 | — | -1107.9% | ||
| Q2 22 | — | -1287.1% |
| Q4 25 | $-0.38 | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $0.14 | ||
| Q4 24 | — | $-0.27 | ||
| Q2 23 | — | $-2.41 | ||
| Q3 22 | — | $-1.79 | ||
| Q2 22 | — | $-1.95 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.7M | $527.4K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $80.0M | $10.2M |
| Total Assets | $140.4M | $2.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.7M | $527.4K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | $3.1M | ||
| Q2 23 | — | $3.2M | ||
| Q3 22 | — | $1.0M | ||
| Q2 22 | — | $1.9M |
| Q4 25 | $80.0M | $10.2M | ||
| Q3 25 | — | $11.1M | ||
| Q2 25 | — | $11.7M | ||
| Q4 24 | — | $11.4M | ||
| Q2 23 | — | $6.4M | ||
| Q3 22 | — | $14.1M | ||
| Q2 22 | — | $15.3M |
| Q4 25 | $140.4M | $2.1M | ||
| Q3 25 | — | $3.1M | ||
| Q2 25 | — | $3.8M | ||
| Q4 24 | — | $3.5M | ||
| Q2 23 | — | $9.5M | ||
| Q3 22 | — | $17.7M | ||
| Q2 22 | — | $18.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.0M | $-568.6K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-13.0M | $-568.6K | ||
| Q3 25 | — | $24.7K | ||
| Q2 25 | — | $-867.5K | ||
| Q4 24 | — | $-716.6K | ||
| Q2 23 | — | $-1.3M | ||
| Q3 22 | — | $-1.7M | ||
| Q2 22 | — | $-2.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1.29× | ||
| Q4 24 | — | — | ||
| Q2 23 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
